Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
-
Narrated by:
-
By:
Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
No reviews yet